Drug Profile
Research programme: immune tolerance-inducing therapeutics - Anokion
Alternative Names: Autoimmune disease therapeutics - Anokion; Cancer therapeutics - Anokion; Diabetes therapeutic - Anokion; Immune-masked protein theraputics - Anokion; Tolerogenic asparaginase - AnokionLatest Information Update: 22 Sep 2023
Price :
$50
*
At a glance
- Originator Anokion
- Class Antigouts; Antihyperglycaemics; Antineoplastics
- Mechanism of Action Antigen presenting cell modulators; Immunomodulators; T lymphocyte inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Autoimmune disorders
- No development reported Cancer; Gout; Type 1 diabetes mellitus
Most Recent Events
- 19 Sep 2023 Pharmacodynamics data from preclinical studies in Autoimmune disorders released by Anokion
- 26 Jun 2023 Preclinical trials in Autoimmune disorders in Switzerland (IV) (Anokion pipeline, June 2023)
- 28 Feb 2023 No recent reports of development identified for research development in Type-1 diabetes mellitus in USA (IV)